Corticotropin-releasing hormone deficiency results in impaired analgesic response during CFA-induced inflammation.
CRH
Cytokine
Glucocorticoid
Inflammation
Pain
Journal
Hormones (Athens, Greece)
ISSN: 2520-8721
Titre abrégé: Hormones (Athens)
Pays: Switzerland
ID NLM: 101142469
Informations de publication
Date de publication:
14 May 2024
14 May 2024
Historique:
received:
10
11
2023
accepted:
25
04
2024
medline:
14
5
2024
pubmed:
14
5
2024
entrez:
13
5
2024
Statut:
aheadofprint
Résumé
Corticotropin-releasing hormone (CRH) plays an important role in relief of pain by releasing analgesia-associated molecules in several inflammatory states. During inflammation, peripheral CRH acts on cells of the immune system to stimulate the local expression of proopiomelanocortin (POMC) and the production of β-endorphin, which in turn binds to opioid receptors on sensory neurons to produce antinociception. In the present study, we further investigated the role of endogenous CRH in inflammatory pain by determining the effects of Crh-deficiency on this process. For this purpose, we used Crh-deficient (Crh-/-) mice and their wildtype (Crh + / +) littermates in the CFA (Complete Freund's Adjuvant)-induced inflammatory pain model. Pain thresholds were evaluated with the Hargreaves apparatus. Our experiments showed that Crh deficiency led to increased pain response, which was associated with decreased POMC mRNA levels in locally inflamed paws of these mice. Furthermore, Crh-/- mice had higher paw edema than Crh + / + mice. Histological evaluation of inflamed paw tissues revealed increased inflammatory response in Crh-/- mice. Protein levels of proinflammatory cytokines, such as IL-6, TNF-α, and IL-1β, were higher in inflamed tissue of Crh-/- mice compared to wildtype mice. Corticosterone replacement increased the pain threshold of Crh-/- mice, restored their paw volume to the levels of wildtype mice, and significantly reduced their proinflammatory cytokine levels. Furthermore, glucocorticoid administration significantly increased POMC mRNA expression in the inflamed paw. Our data suggest that genetic deficiency of CRH is associated with increased pain. This effect is likely attributable to the accompanying glucocorticoid insufficiency and is in part mediated by opioids expressed locally.
Identifiants
pubmed: 38740711
doi: 10.1007/s42000-024-00565-8
pii: 10.1007/s42000-024-00565-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Stein C, Gramsch C, Hassan AH, Przewlocki R, Parsons CG, Peter K, Herz A (1990) Local opioid receptors mediating antinociception in inflammation: endogenous ligands. Prog Clin Biol Res 328:425–427
pubmed: 1968271
Stein C, Gramsch C, Herz A (1990) Intrinsic mechanisms of antinociception in inflammation: local opioid receptors and beta-endorphin. J Neurosci 10(4):1292–1298. https://doi.org/10.1523/JNEUROSCI.10-04-01292.1990
doi: 10.1523/JNEUROSCI.10-04-01292.1990
pubmed: 2158530
pmcid: 6570200
Rittner HL, Brack A, Machelska H, Mousa SA, Bauer M, Schafer M, Stein C (2001) Opioid peptide-expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. Anesthesiology 95(2):500–508. https://doi.org/10.1097/00000542-200108000-00036
doi: 10.1097/00000542-200108000-00036
pubmed: 11506126
Sitte N, Busch M, Mousa SA, Labuz D, Rittner H, Gore C, Krause H, Stein C, Schafer M (2007) Lymphocytes upregulate signal sequence-encoding proopiomelanocortin mRNA and beta-endorphin during painful inflammation in vivo. J Neuroimmunol 183(1–2):133–145. https://doi.org/10.1016/j.jneuroim.2006.11.033
doi: 10.1016/j.jneuroim.2006.11.033
pubmed: 17223201
Sibinga NE, Goldstein A (1988) Opioid peptides and opioid receptors in cells of the immune system. Annu Rev Immunol 6:219–249. https://doi.org/10.1146/annurev.iy.06.040188.001251
doi: 10.1146/annurev.iy.06.040188.001251
pubmed: 2838048
Przewlocki R, Hassan AH, Lason W, Epplen C, Herz A, Stein C (1992) Gene expression and localization of opioid peptides in immune cells of inflamed tissue: functional role in antinociception. Neuroscience 48(2):491–500. https://doi.org/10.1016/0306-4522(92)90509-z
doi: 10.1016/0306-4522(92)90509-z
pubmed: 1603330
Venihaki M, Zhao J, Karalis KP (2003) Corticotropin-releasing hormone deficiency results in impaired splenocyte response to lipopolysaccharide. J Neuroimmunol 141(1–2):3–9. https://doi.org/10.1016/s0165-5728(03)00183-8
doi: 10.1016/s0165-5728(03)00183-8
pubmed: 12965248
Karalis K, Muglia LJ, Bae D, Hilderbrand H, Majzoub JA (1997) CRH and the immune system. J Neuroimmunol 72(2):131–136. https://doi.org/10.1016/s0165-5728(96)00178-6
doi: 10.1016/s0165-5728(96)00178-6
pubmed: 9042104
Karalis K, Sano H, Redwine J, Listwak S, Wilder RL, Chrousos GP (1991) Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 254(5030):421–423. https://doi.org/10.1126/science.1925600
doi: 10.1126/science.1925600
pubmed: 1925600
Mousa SA, Schafer M, Mitchell WM, Hassan AH, Stein C (1996) Local upregulation of corticotropin-releasing hormone and interleukin-1 receptors in rats with painful hindlimb inflammation. Eur J Pharmacol 311(2–3):221–231. https://doi.org/10.1016/0014-2999(96)00440-2
doi: 10.1016/0014-2999(96)00440-2
pubmed: 8891603
Yarushkina NI, Bagaeva TR, Filaretova LP (2009) Analgesic actions of corticotropin-releasing factor (CRF) on somatic pain sensitivity: involvement of glucocorticoid and CRF-2 receptors. Neurosci Behav Physiol 39(9):819–823. https://doi.org/10.1007/s11055-009-9212-9
doi: 10.1007/s11055-009-9212-9
pubmed: 19830568
Galin FS, LeBoeuf RD, Blalock JE (1991) Corticotropin-releasing factor upregulates expression of two truncated pro-opiomelanocortin transcripts in murine lymphocytes. J Neuroimmunol 31(1):51–58. https://doi.org/10.1016/0165-5728(91)90086-m
doi: 10.1016/0165-5728(91)90086-m
pubmed: 1845769
Schafer M, Mousa SA, Zhang Q, Carter L, Stein C (1996) Expression of corticotropin-releasing factor in inflamed tissue is required for intrinsic peripheral opioid analgesia. Proc Natl Acad Sci USA 93(12):6096–6100. https://doi.org/10.1073/pnas.93.12.6096
doi: 10.1073/pnas.93.12.6096
pubmed: 8650225
pmcid: 39195
Yarushkina NI, Filaretova LP (2018) The peripheral corticotropin-releasing factor (CRF)-induced analgesic effect on somatic pain sensitivity in conscious rats: involving CRF, opioid and glucocorticoid receptors. Inflammopharmacology 26(2):305–318. https://doi.org/10.1007/s10787-018-0445-5
doi: 10.1007/s10787-018-0445-5
pubmed: 29404882
Kiang JG, Wei ET (1987) Corticotropin-releasing factor inhibits thermal injury. J Pharmacol Exp Ther 243(2):517–520
pubmed: 3500298
Hargreaves KM, Dubner R, Costello AH (1989) Corticotropin releasing factor (CRF) has a peripheral site of action for antinociception. Eur J Pharmacol 170(3):275–279. https://doi.org/10.1016/0014-2999(89)90550-5
doi: 10.1016/0014-2999(89)90550-5
pubmed: 2620699
Likar R, Mousa SA, Steinkellner H, Koppert W, Philippitsch G, Stein C, Schafer M (2007) Involvement of intra-articular corticotropin-releasing hormone in postoperative pain modulation. Clin J Pain 23(2):136–142. https://doi.org/10.1097/01.ajp.0000210954.93878.0d
doi: 10.1097/01.ajp.0000210954.93878.0d
pubmed: 17237662
Venihaki M, Majzoub J (2002) Lessons from CRH knockout mice. Neuropeptides 36(2–3):96–102. https://doi.org/10.1054/npep.2002.0906
doi: 10.1054/npep.2002.0906
pubmed: 12359501
Muglia L, Jacobson L, Dikkes P, Majzoub JA (1995) Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature 373(6513):427–432. https://doi.org/10.1038/373427a0
doi: 10.1038/373427a0
pubmed: 7830793
Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32(1):77–88. https://doi.org/10.1016/0304-3959(88)90026-7
doi: 10.1016/0304-3959(88)90026-7
pubmed: 3340425
Poulaki S, Rassouli O, Liapakis G, Gravanis A, Venihaki M (2021) Analgesic and Anti-Inflammatory Effects of the Synthetic Neurosteroid Analogue BNN27 during CFA-Induced Hyperalgesia. Biomedicines 9(9). https://doi.org/10.3390/biomedicines9091185 .
Osborne NR, Davis KD (2022) Sex and gender differences in pain. Int Rev Neurobiol 164:277–307. https://doi.org/10.1016/bs.irn.2022.06.013
doi: 10.1016/bs.irn.2022.06.013
pubmed: 36038207
Schafer M, Carter L, Stein C (1994) Interleukin 1 beta and corticotropin-releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue. Proc Natl Acad Sci USA 91(10):4219–4223. https://doi.org/10.1073/pnas.91.10.4219
doi: 10.1073/pnas.91.10.4219
pubmed: 7910403
pmcid: 43756
Kapitzke D, Vetter I, Cabot PJ (2005) Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control. Ther Clin Risk Manag 1(4):279–297
pubmed: 18360571
pmcid: 1661636
Mousa SA, Shaqura M, Khalefa BI, Li L, Al-Madol M, Treskatsch S, Schafer M (2021) Functional and anatomical characterization of corticotropin-releasing factor receptor subtypes of the rat spinal cord involved in somatic pain relief. Mol Neurobiol 58(11):5459–5472. https://doi.org/10.1007/s12035-021-02481-z
doi: 10.1007/s12035-021-02481-z
pubmed: 34331656
pmcid: 8599353
Venihaki M, Dikkes P, Carrigan A, Karalis KP (2001) Corticotropin-releasing hormone regulates IL-6 expression during inflammation. J Clin Invest 108(8):1159–1166. https://doi.org/10.1172/JCI12869
doi: 10.1172/JCI12869
pubmed: 11602623
pmcid: 209527
Rittner HL, Stein C (2005) Involvement of cytokines, chemokines and adhesion molecules in opioid analgesia. Eur J Pain 9(2):109–112. https://doi.org/10.1016/j.ejpain.2004.05.009
doi: 10.1016/j.ejpain.2004.05.009
pubmed: 15737796
Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S (1997) Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol 121(3):417–424. https://doi.org/10.1038/sj.bjp.0701148
doi: 10.1038/sj.bjp.0701148
pubmed: 9179382
pmcid: 1564704
Opree A, Kress M (2000) Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, IL-1 beta, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. J Neurosci 20(16):6289–6293. https://doi.org/10.1523/JNEUROSCI.20-16-06289.2000
doi: 10.1523/JNEUROSCI.20-16-06289.2000
pubmed: 10934280
pmcid: 6772609
Oka T, Oka K, Hosoi M, Hori T (1995) Intracerebroventricular injection of interleukin-6 induces thermal hyperalgesia in rats. Brain Res 692(1–2):123–128. https://doi.org/10.1016/0006-8993(95)00691-i
doi: 10.1016/0006-8993(95)00691-i
pubmed: 8548295
Danenberg HD, Alpert G, Lustig S, Ben-Nathan D (1992) Dehydroepiandrosterone protects mice from endotoxin toxicity and reduces tumor necrosis factor production. Antimicrob Agents Chemother 36(10):2275–2279. https://doi.org/10.1128/AAC.36.10.2275
doi: 10.1128/AAC.36.10.2275
pubmed: 1444309
pmcid: 245489
Bethin KE, Vogt SK, Muglia LJ (2000) Interleukin-6 is an essential, corticotropin-releasing hormone- independent stimulator of the adrenal axis during immune system activation. Proc Natl Acad Sci USA 97(16):9317–9322. https://doi.org/10.1073/pnas.97.16.9317
doi: 10.1073/pnas.97.16.9317
pubmed: 10922080
pmcid: 16865
Stradecki HM, Jaworski DM (2011) Hyperphagia and leptin resistance in tissue inhibitor of metalloproteinase-2 deficient mice. J Neuroendocrinol 23(3):269–281. https://doi.org/10.1073/pnas.97.16.9317
doi: 10.1073/pnas.97.16.9317
pubmed: 21175899
pmcid: 3042479
Wen T, Peng B, Pintar JE (2009) The MOR-1 opioid receptor regulates glucose homeostasis by modulating insulin secretion. Mol Endocrinol 23(5):671–678. https://doi.org/10.1210/me.2008-0345
doi: 10.1210/me.2008-0345
pubmed: 19221053
pmcid: 2675956
Pol O, Palacio JR, Puig MM (2003) The expression of delta- and kappa-opioid receptor is enhanced during intestinal inflammation in mice. J Pharmacol Exp Ther 306(2):455–462. https://doi.org/10.1124/jpet.103.049346
doi: 10.1124/jpet.103.049346
pubmed: 12724348
Dermitzaki E, Liapakis G, Androulidaki A, Venihaki M, Melissas J, Tsatsanis C, Margioris AN (2014) Corticotrophin-Releasing Factor (CRF) and the urocortins are potent regulators of the inflammatory phenotype of human and mouse white adipocytes and the differentiation of mouse 3T3L1 pre-adipocytes. PLoS ONE 9(5):e97060. https://doi.org/10.1371/journal.pone.0097060
doi: 10.1371/journal.pone.0097060
pubmed: 24835211
pmcid: 4024041